⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL578026 | 0.74 | — | — | |
| SCHEMBL30491083 | 0.74 | — | — | |
| SCHEMBL31452225 | 0.74 | — | — | |
| SCHEMBL6912131 | 0.74 | — | — | |
| SCHEMBL17285647 | 0.74 | — | — | |
| SCHEMBL25292508 | 0.74 | — | — | |
| SCHEMBL9157488 | 0.74 | — | — | |
| SCHEMBL156190 | 0.74 | — | — | |
| SCHEMBL18318562 | 0.73 | CCR1 (0.34) | — | |
| Hydrochloric Acid SCHEMBL6604967 | 0.72 | RAB9A (0.42) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 370 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102898358-A | Preparation method of fluoropyridine compounds | SHANGHAI TITAN TECHNOLOGY CO LTD | 2013-01-30 | — | — | CN | claimed |
| CN-119707952-B | Thiadiazolidinone derivative with PTPN2/PTPN1 inhibitory activity, and preparation method and application thereof | CHINA PHARMACEUTICAL UNIVERSITY (CN) | 2026-05-26 | — | — | CN | disclosed |
| US-20260132140-A1 | IMIDAZOLYL-AMINO-PYRAZINE-CARBONITRILS AS CHK-1 INHIBITORS | BENEVOLENTAI BIO LTD (GB) | 2026-05-14 | — | — | US | disclosed |
| EP-4720071-A1 | COMPOUNDS FOR THE DEGRADATION OF EGFR KINASE | Beone Medicines I GmbH (CH) | 2026-04-08 | — | — | EP | disclosed |
| EP-4676927-A1 | HETEROCYCLIC COMPOUNDS AS WRN INHIBITORS | Synnovation Therapeutics, Inc. (US) | 2026-01-14 | — | — | EP | disclosed |
| US-20250346609-A1 | COT MODULATORS AND METHODS OF USE THEREOF | GILEAD SCIENCES INC (US) | 2025-11-13 | — | — | US | disclosed |
| EP-4626864-A1 | LINEAR HETEROARYL DIAMIDE IRE1/XBP1S ACTIVATORS | Protego Biopharma, Inc. (US) | 2025-10-08 | — | — | EP | disclosed |
| EP-4620955-A1 | MC4R ANTAGONIST COMPOUND, PHARMACEUTICAL COMPOSITION AND PHARMACEUTICAL USE THEREOF | Changchun Genescience Pharmaceutical Co., Ltd. (CN) | 2025-09-24 | — | — | EP | disclosed |
| US-12421228-B2 | Naphthyridine derivatives as PRC2 inhibitors | Mirati Therapeutics, Inc. (US) | 2025-09-23 | — | — | US | disclosed |
| US-20250282787-A1 | SUBSTITUTED IMIDAZO[1,2-c]PYRIMIDINES AS PRC2 INHIBITORS | Mirati Therapeutics, Inc. | 2025-09-11 | — | — | US | disclosed |
| EP-2114935-B1 | PIPERIDINE GPCR AGONISTS | PROSIDION LTD (GB) | 2011-07-20 | — | — | EP | disclosed |
| CN-102083813-A | Piperidinyl gpcr agonists | PROSIDION LTD | 2011-06-01 | — | — | CN | disclosed |
| EP-2254892-A1 | BICYCLIC NITROIMIDAZOLES COVALENTLY LINKED TO SUBSTITUTED PHENYL OXAZOLIDINONES | Global Alliance For Tb Drug Development (US) | 2010-12-01 | — | — | EP | disclosed |
| US-20100105732-A1 | PIPERIDINE GPCR AGONISTS | PROSIDION LIMITED (GB) | 2010-04-29 | — | — | US | disclosed |
| US-7666864-B2 | Bicyclic nitroimidazole-substituted phenyl oxazolidinones | GLOBAL ALLIANCE FOR TB DRUG DEVELOPMENT (US) | 2010-02-23 | — | — | US | disclosed |
| WO-2010004345-A1 | PIPERIDINYL GPCR AGONISTS | PROSIDION LIMITED (GB) | 2010-01-14 | — | — | WO | disclosed |
| US-20090281088-A1 | BICYCLIC NITROIMIDAZOLE-SUBSTITUTED PHENYL OXAZOLIDINONES | GLOBAL ALLIANCE FOR TB DRUG DEVELOPMENT (US) | 2009-11-12 | — | — | US | disclosed |
| EP-2114935-A1 | PIPERIDINE GPCR AGONISTS | Prosidion Limited (GB) | 2009-11-11 | — | — | EP | disclosed |
| WO-2009120789-A1 | BICYCLIC NITROIMIDAZOLES COVALENTLY LINKED TO SUBSTITUTED PHENYL OXAZOLIDINONES | GLOBAL ALLIANCE FOR TB DRUG DEVELOPMENT (US) | 2009-10-01 | — | — | WO | disclosed |
| WO-2008081207-A1 | PIPERIDINE GPCR AGONISTS | PROSIDION LIMITED (GB) | 2008-07-10 | — | — | WO | disclosed |